Return to homepagePandemic Pact

Effect of drug use before and during SARS-COV-2 infection on the evolution of patients with COVID-19. A population-based cohort study.

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00470

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Adolfo Figueiras Guzmán

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACIÇÿN INSTITUTO INVESTIGACIÇÿN SANITARIA DE SANTIAGO DE COMPOSTELA

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

There are important inconsistencies and lack of evidence on the effect of treatment with antihypertensive drugs of the ACEI and / or AIIRA type and some NSAIDs could be a risk factor for severity and even mortality from COVID-19. This favors rumors and errors in information, which can negatively affect Public Health and decision-making. Therefore, with this study we intend to assess whether the previous consumption of certain medications (ACEIs, ARA 2 conditions a greater susceptibility to infection by SARS-COV-2; and to identify those treatments received before and after the infection that are associated with a better evolution and greater survival.For this, Galician population registers will be used, through the HEXIN big data platform.